Ivonescimab phase three trials reduce death risk by 34 per cent, as analysts predict it could transform non-small cell lung cancer therapy
2-MIN READ2-MIN ListenJulie ZhangPublished: 6:49pm, 1 Jun 2026Akeso, whose drug ivonescimab was hailed as biotech’s “DeepSeek moment” amid US competition last year, announced better-than-expected clinical results showing it can treat a type of lung cancer commonly found in smokers, potentially expanding its approved uses.Analysts suggest it could become a backbone therapy in the US$20 billion global non-small cell lung cancer market and have revised their target prices upwards.
The drug’s phase three trial found that ivonescimab reduced the risk of death by 34 per cent, according to a filing with the Hong Kong stock exchange on Monday.
However, its Hong Kong-listed shares dropped 1.86 per cent to HK$115.9 apiece, bucking the market rally as the Hang Seng Index gained about 0.86 per cent on Monday.
Nearly two-thirds of the patients – 64.7 per cent – were still alive two years after taking ivonescimab, compared with less than half, or 48.6 per cent, in the control group.
